Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 14'th Jun 2024
SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
06:32am, Thursday, 23'rd May 2024
89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver f
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 10'th May 2024
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializati
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Thursday, 09'th May 2024
–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients–
89bio to Participate in the BofA Securities 2024 Health Care Conference
04:05pm, Wednesday, 08'th May 2024
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
01:01pm, Monday, 06'th May 2024
89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH
04:05pm, Thursday, 02'nd May 2024
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
04:05pm, Wednesday, 17'th Apr 2024
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Apr 2024
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializa
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling
—Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients—
Buffett Loads Up on This Stock Again, Plus CEO Insider Buying
09:50am, Sunday, 10'th Mar 2024
In the wake of a media giant's quarterly report, the Oracle of Omaha is again bolstering his stake in the tracking stocks with some huge insider purchases.
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th Mar 2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializa
